Nytamel (Zolpidem Hemitartrate)

Zolpidem hemitartrate selectively binds to the benzodiazepine site on GABA‑A receptors, enhancing the inhibitory effect of GABA. This increased chloride influx produces a sedative‑hypnotic response that promotes sleep initiation without markedly changing normal sleep stages.

The appropriate dose of Nytmel is determined by a qualified prescriber based on the individual’s clinical condition, age, liver function and concomitant medications. Patients should follow the prescribing information provided by their healthcare professional.

Zolpidem hemitartrate is classified as a pregnancy‑category C medication. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To order Nytmel, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nytmel (zolpidem) is a non‑benzodiazepine sedative‑hypnotic that acts more selectively at the GABA‑A receptor, offering rapid onset of sleep with fewer effects on sleep architecture compared with many benzodiazepines. It is generally preferred for short‑term use due to its lower risk of dependence.

Store Nytmel tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Nytmel is taken orally, usually as a single tablet shortly before bedtime. It should be taken on an empty stomach with no more than a small amount of food, and patients should ensure they have a full night’s sleep opportunity (7‑8 hours) before any required activity.

Serious risks include complex sleep‑related behaviours such as sleep‑walking or driving while not fully awake, severe allergic reactions, respiratory depression especially when combined with other depressants, and rare psychiatric effects like depression or suicidal thoughts.

Nytmel is contraindicated in individuals with known hypersensitivity to zolpidem or any tablet excipients, severe hepatic impairment, and patients who have experienced complex sleep behaviours with zolpidem. Caution is also advised for the elderly and those with a history of substance misuse.